

**American College of Emergency Physicians**  
**Clinical Policies Committee Conference Call**  
**July 21, 2021**

**MINUTES**

**Participants**

Committee members participating in all or part of the meeting: Stephen J. Wolf, MD, FACEP, Chair; Richard Byyny, MD, MSc, FACEP, Methodologist; Stephen V. Cantrill, MD, FACEP, Liaison with Quality & Patient Safety Committee, and to the E-QUAL Steering Committee; Christopher R. Carpenter, MD, MSc, FACEP; John T. Finnell, MD, FACEP, FACMI, Board Liaison; Seth R. Gemme, MD, FACEP; Charles J. Gerardo, MD, MHS, FACEP; Steven A. Godwin, MD, FACEP; Sigrid A. Hahn, MD, MPH; Amy Kaji, MD, MPH, PhD, Methodologist; Bruce M. Lo, MD, MBA, RDMS, FACEP; Sharon E. Mace, MD, FACEP, FAAP; Kaushal H. Shah, MD, FACEP; Richard D. Shih, MD, FACEP; Michael D. Smith, MD, MBA, FACEP; Molly E.W. Thiessen, MD, FACEP; Christian Tomaszewski, MD, MS, MBA, FACEP; Stephen P. Wall, MD, MSc, MAEd, FACEP; Yanling Yu, PhD, Advocate for Patient Safety.

Also present for all or part of the meeting: Lauren Westafer, DO, MPH, MS, Writing Committee on High Sensitivity Troponin; Travis Schulz, MLS, AHIP, Staff Liaison; Kaeli Vandertulip, MSLS, MBA, AHIP, Staff Liaison.

**Agenda**

1. Disclosures
2. High-sensitivity Troponin Policy Statement and PREP

**Minutes**

1. Dr. Tomazewski declared he was the primary investigator for a study of Roche Diagnostic's Gen 6 high-sensitivity troponin. Dr. Tomazewski contributed his experience to the content development of the high-sensitivity troponin policy statement; however, there was no Committee vote on the topic that would have required his abstention from voting. No other disclosures pertinent to the agenda were declared.
2. Dr. Gemme led the discussion on the draft for the high-sensitivity troponin policy statement with assistance from members of the writing committee present (Dr. Westafer). The Committee suggested edits to the draft. The writing committee will incorporate the suggested changes and the Committee with review and revised the draft.